Real-world practice of obstetricians in respect of assays for antiphospholipid antibodies

被引:1
|
作者
Sugiura-Ogasawara, Mayumi [1 ]
Atsumi, Tatsuya [2 ]
Yamada, Hideto [3 ]
Kitaori, Tamao [1 ]
Ozaki, Yasuhiko [1 ]
Katano, Kinue [1 ]
Murashima, Atsuko [4 ]
机构
[1] Nagoya City Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Nagoya, Aichi 4678601, Japan
[2] Hokkaido Univ, Grad Sch Med, Dept Rheumatol Endocrinol & Nephrol, Sapporo, Hokkaido, Japan
[3] Kobe Univ, Grad Sch Med, Dept Obstet & Gynecol, Kobe, Hyogo 657, Japan
[4] Natl Ctr Child Hlth & Dev, Ctr Maternal Fetal Neonatal & Reprod Med, Tokyo, Japan
关键词
Antiphospholipid antibody; lupus anticoagulant; obstetric antiphospholipid syndrome; recurrent pregnancy loss; survey; RECURRENT PREGNANCY LOSS; ASPIRIN PLUS HEPARIN; LUPUS ANTICOAGULANT; ANTICARDIOLIPIN ANTIBODIES; WOMEN; AUTOANTIBODIES; PREDICTOR; RECOGNIZE; UPDATE; TRIAL;
D O I
10.3109/14397595.2015.1023978
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. The international classification criteria (CC) for definite antiphospholipid syndrome (APS) recommend confirmation of the sustained presence, for at least 12 weeks, of both lupus anticoagulant (LA), as determined by aPTT and RVVT, and anti beta 2glycoprotein I (beta 2GPI) or anticardiolipin (aCL) IgG and/or IgM. However, it remains unclear whether obstetricians comply with the aforementioned CC for the diagnosis of APS in daily clinical practice. We performed a nationwide survey to examine the attitudes of Japanese obstetricians toward the use of assays for antiphospholipid antibodies (aPLs). Methods. A questionnaire was sent to 2,700 obstetric facilities where maternity checkups are car-ried out. The types of assays conducted for aPLs, ascertainment of persistence of the antibodies for at least 12 weeks, and the cutoff points used for the assays were examined. Results. Of the facilities surveyed, 61.5% carried out the assay(s) only once. In regard to the type of assay performed, 97.1% carried out the assay for aCL IgG and/or beta 2GPI-dependent aCL, while 67.9% performed the LA-aPTT and/or LA-RVVT assay. Only 8.8% carried out assays for both LA. As for the cutoff points used, 98% of the facilities used lower cutoff points described in the manufacturers' manuals rather than the cutoff values recommended in the CC. Conclusion. Thus, only a limited number of facilities adhered precisely to the CC for the diagnosis of APS. Inappropriate treatment and unnecessary expense are potentially major concerns when facilities overdiagnose APS using lower cutoff points or without ascertaining the persistence of the antibodies for at least 12 weeks. On the other hand, some patients miss the opportunity to be treated for APS because of the absence of testing for LA.
引用
收藏
页码:883 / 887
页数:5
相关论文
共 50 条
  • [11] CAN TESTS FOR IGA, IGG, OR IGM ANTIBODIES TO CARDIOLIPIN OR PHOSPHATIDYLSERINE SUBSTITUTE FOR LUPUS ANTICOAGULANT ASSAYS IN SCREENING FOR ANTIPHOSPHOLIPID ANTIBODIES
    COWCHOCK, FS
    FORT, JG
    AUTOIMMUNITY, 1994, 17 (02) : 119 - 122
  • [12] For insights into the real world, consider real-world data
    Raoof, Sana
    Kurzrock, Razelle
    SCIENCE TRANSLATIONAL MEDICINE, 2022, 14 (673)
  • [13] ANTIPHOSPHOLIPID ANTIBODIES AND THROMBOSIS IN SYSTEMIC LUPUS-ERYTHEMATOSUS - COMPARISON OF 3 LUPUS ANTICOAGULANT ASSAYS AND ANTICARDIOLIPIN ELISA IN 188 PATIENTS
    JOUHIKAINEN, T
    JULKUNEN, H
    VAARALA, O
    LEIRISALOREPO, M
    STEPHANSSON, E
    VAHTERA, E
    PALOSUO, T
    MYLLYLA, G
    BLOOD COAGULATION & FIBRINOLYSIS, 1992, 3 (04) : 407 - 414
  • [14] Indication and outcome of lupus anticoagulant and antiphospholipid antibodies testing in routine clinical practice
    Kempers, Eva K.
    Dalm, Virgil A. S. H.
    van Rijn, Marie Josee E.
    Mulders, Annemarie G. M. G. J.
    Leebeek, Frank W. G.
    de Maat, Moniek P. M.
    Jansen, A. J. Gerard
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2021, 5 (03)
  • [15] High frequency of inadequate test requests for antiphospholipid antibodies in daily clinical practice
    Mameli, Antonella
    Barcellona, Doris
    Vannini, Maria Luigia
    Marongiu, Francesco
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 (04) : 695 - 698
  • [16] Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice
    Hulin, Cyrille
    de la Rubia, Javier
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Katodritou, Eirini
    Hungria, Vania
    De Samblanx, Hadewijch
    Stoppa, Anne-Marie
    Aagesen, Jesper
    Sargin, Deniz
    Sioni, Anastasia
    Belch, Andrew
    Diels, Joris
    Olie, Robert A.
    Robinson, Don, Jr.
    Potamianou, Anna
    van de Velde, Helgi
    Delforge, Michel
    HEALTH SCIENCE REPORTS, 2019, 2 (01)
  • [17] Comparison between real-world practice and application of the FRAX algorithm in the treatment of osteoporosis
    Zoccarato, Francesca
    Ceolin, Chiara
    Trevisan, Caterina
    Citron, Anna
    Haxhiaj, Labjona
    Guarnaccia, Aurelio
    Panozzo, Matteo
    Campodall'Orto, Carlotta
    Coin, Alessandra
    Giannini, Sandro
    Sergi, Giuseppe
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 34 (11) : 2807 - 2814
  • [18] Domestic Violence Risk Assessment Research to Real-World Practice: The Devil Is in the Implementation
    Youngson, Nicole
    Saxton, Michael
    Jaffe, Peter G.
    Kielt, Lyara
    Olszowy, Laura
    Dawson, Myrna
    Straatman, Anna-Lee
    VIOLENCE AND VICTIMS, 2022, 37 (04) : 425 - 440
  • [19] Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice
    Singh, Aditi P.
    Shum, Elaine
    Rajdev, Lakshmi
    Cheng, Haiying
    Goel, Sanjay
    Perez-Soler, Roman
    Halmos, Balazs
    CANCERS, 2020, 12 (05)
  • [20] Testing for Antiphospholipid antibodies with Solid Phase Assays: guidance from the SSC of the ISTH
    Devreese, K. M. J.
    Pierangeli, S. S.
    De Laat, B.
    Tripodi, A.
    Atsumi, T.
    Ortel, T. L.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (05) : 792 - 795